Matrix45, Tucson, AZ 85743, USA.
Center for Health Outcomes & PharmacoEconomic Research, University of Arizona, Tucson, AZ 85721, USA.
Future Oncol. 2021 Nov;17(33):4561-4570. doi: 10.2217/fon-2021-0718. Epub 2021 Aug 12.
To estimate the cost-savings from conversion to biosimilar pegfilgrastim-cbqv that can be reallocated to provide budget-neutral expanded access to FOLFIRINOX in patients with metastatic pancreatic cancer. Simulation modeling in a panel of 2500 FOLFIRINOX-treated patients, using varying treatment duration (1-12 cycles) and conversion rates (10-100%), to estimate cost-savings and additional FOLFIRINOX treatment that could be budget neutral. In a 2500-patient panel at 100% conversion, savings of US$6,907.41 per converted patient over 12 cycles of prophylaxis translate to US$17.3 million and could provide 72,273 additional FOLFIRINOX doses or 6023 full 6-month regimens. Conversion to biosimilar CIN/FN prophylaxis can generate significant cost-savings and provide budget-neutral expanded access to FOLFIRINOX treatment for patients with metastatic pancreatic cancer.
估计将培非格司亭-cbqv 转换为生物类似药后可节省的成本，并将其重新分配用于为转移性胰腺癌患者提供预算中性的扩展 FOLFIRINOX 治疗方案。使用不同的治疗持续时间（1-12 个周期）和转换率（10-100%），在 2500 名 FOLFIRINOX 治疗患者的小组中进行模拟建模，以估计节省的成本和可实现预算中性的额外 FOLFIRINOX 治疗方案。在 100%转化率的 2500 名患者小组中，每例接受 12 个周期预防治疗的患者转换后的节省费用为 6907.41 美元，这相当于 1730 万美元，可提供 72273 剂额外的 FOLFIRINOX 治疗方案或 6023 个完整的 6 个月疗程。转换为生物类似药 CIN/FN 预防治疗可以节省大量成本，并为转移性胰腺癌患者提供预算中性的扩展 FOLFIRINOX 治疗方案。
Zotero 插件